- ►annals.org [PDF] MD Schleinitz, PA Heidenreich - Annals of internal medicine, 2005 - Am Coll Physicians A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for ...
High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus ... Mark D.
Schleinitz, MD, MS, and Paul A. Heidenreich, MD, MS Cited by 69 - Related articles - All 12 versions
- ►onlinejacc.org WS Weintraub, EM Mahoney, A Lamy, S Culler, … - Journal of the American College of Cardiology, 2005 - Elsevier The efficacy of platelet inhibition with clopidogrel for up to one year after
ACS was demonstrated in the Clopidogrel in Unstable angina to prevent Recurrent
Events (CURE) trial, a randomized trial of 12,562 patients in 28 countries ... Cited by 52 - Related articles - All 9 versions
J Karnon, A Bakhai, A Brennan, A Pandor, M … - International journal of cardiology, 2006 - Elsevier To assess the long-term cost effectiveness of 1 year's treatment with
clopidogrel on top of standard therapy (including aspirin; ASA) compared with
standard therapy alone, in patients diagnosed with non-ST-segment-elevation ... Cited by 22 - Related articles - All 15 versions
EM Mahoney, S Mehta, Y Yuan, J Jackson, R … - American Heart Journal, 2006 - Elsevier The superiority of clopidogrel and aspirin versus aspirin alone for up to 1 year
in patients who undergo percutaneous coronary intervention (PCI) after
presenting with acute coronary syndromes without ST-segment elevation was ... Cited by 30 - Related articles - All 7 versions
- ►onlinejacc.org PA Cowper, K Udayakumar, MH Sketch, ED … - Journal of the American College of Cardiology, 2005 - Elsevier Using decision analysis, we compared the outcomes and cost of prolonging
clopidogrel treatment from one month to one year after PCI with the alternative
strategy of discontinuing therapy one month after the procedure. Event ... Cited by 39 - Related articles - All 7 versions
[CITATION] A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute …
- ►onlinejacc.org SC Beinart, P Kolm, E Veledar, Z Zhang, EM … - Journal of the American College of Cardiology, 2005 - Elsevier The Clopidogrel for the Reduction of Events During Observation (CREDO) trial, a
randomized trial of 2,116 patients, showed the effectiveness of antiplatelet
therapy with clopidogrel 300 mg before PCI and 75 mg daily for one year ... Cited by 62 - Related articles - BL Direct - All 25 versions
A Ringborg, P Lindgren, B Jönsson - The European Journal of Health Economics, 2005 - Springer P atients un dergoing percutane ous cor- onary intervention (PCI) are at risk of
acute, sub acute, and long-term thrombot- ic events. Antiplate let agents playa
criti cal role in preventing these events, the most com mon of which lead ... Cited by 17 - Related articles - BL Direct - All 3 versions
P Lindgren, U Stenestrand, K Malmberg, B … - Clinical therapeutics, 2005 - Elsevier The Percutaneous CoronaryIntervention-Clopidogrel in Unstable Angina to Prevent
Recurrent Events (PCI-CURE) study, which examined the effect of adding
clopidogrel to aspirin versus aspirin alone in patients with unstable ... Cited by 27 - Related articles - All 4 versions
- ►emcreg.org [PDF] P Tricoci, MT Roe, J Mulgund, LK Newby, SC … - Archives of Internal Medicine, 2006 - Am Med Assoc Methods We studied 61 052 patients with high-risk NSTE ACS (defined as the
presence of positive cardiac markers and/or ischemic ST-segment changes) from
January 2002 through December 2003 at 461 US hospitals participating in the ... Cited by 38 - Related articles - BL Direct - All 6 versions
